American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

LOXO-305 in Previously Treated CLL/SLL: Safety and Early Efficacy Data from the BRUIN Trial

ASH 2020 – CLL: Wrap-Up

The noncovalent BTK inhibitor LOXO-305 demonstrated promising efficacy in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). LOXO-305 was well-tolerated and active in patients following multiple prior lines of therapy, including patients with and without BTK C481 mutations. Read More ›

CPX-351 plus Venetoclax in Patients with Acute Myeloid Leukemia: A Phase 2 Study

ASH 2020 – AML

CPX-351 plus 7 days of venetoclax was tolerable and demonstrated encouraging activity in patients with relapsed/refractory acute myeloid leukemia. Read More ›

Safety and Efficacy of CD19-CAR T-Cells in Richter’s Transformation Following Targeted Therapy for CLL

ASH 2020 – CLL: Wrap-Up

Treatment with CD19-CAR T-cells in patients with chronic lymphocytic leukemia (CLL) and disease transformation was found to be safe and demonstrates a high rate of complete remission. Read More ›

Treating First AML Low Blast Count Relapse with Escalated Dosing Schedules of CC-486 Is Effective and Well-Tolerated

ASH 2020 – AML

An escalated 21-day CC-486 (oral azacitidine) dosing regimen was well-tolerated and restored remission in approximately 25% of patients with acute myeloid leukemia (AML) who relapsed with 5% to 15% blasts on-study in the QUAZAR AML-001 trial. Read More ›

Umbralisib plus Ublituximab in Patients with Treatment-Naïve and Relapsed or Refractory CLL

ASH 2020 – CLL: Wrap-Up

The combination of umbralisib and ublituximab, referred to as U2, was well-tolerated and significantly improved progression-free survival when compared with standard of care in patients with both treatment-naïve and relapsed or refractory chronic lymphocytic leukemia (CLL). Read More ›

A Comparison of the Effectiveness of Glasdegib versus Venetoclax in Combination with Low-Dose Ara-C

ASH 2020 – AML

Overall survival hazard ratios based on adjusted simulated treatment comparisons numerically, but not statistically, favored glasdegib plus low-dose cytarabine (LDAC) over venetoclax plus LDAC. Read More ›

Prognostic Biomarker Testing, Treatment Patterns, and Dosing Among Patients with CLL/SLL

ASH 2020 – CLL: Wrap-Up

The informCLL registry of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) can help to resolve knowledge gaps that may be identified in the evaluation and treatment of patients with CLL/SLL. Read More ›

Venetoclax plus Decitabine versus Intensive Chemotherapy for Treating Relapsed/Refractory AML

ASH 2020 – AML

As salvage therapy in younger patients with relapsed/refractory acute myeloid leukemia (AML), the efficacy of 10-day decitabine + venetoclax is comparable to intensive chemotherapy regimens and is an appropriate bridge to allogeneic stem-cell transplantation. Read More ›

Ibrutinib plus Venetoclax for First-Line Treatment of CLL/SLL: Results from the CAPTIVATE Study

ASH 2020 – CLL: Wrap-Up

Primary results from the CAPTIVATE study demonstrate that fixed-duration treatment with ibrutinib plus venetoclax offers treatment-free remission for patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Read More ›

FLAG-IDA Intensive Induction/Consolidation plus Venetoclax in Newly Diagnosed or R/R AML Patients

ASH 2020 – AML

Across multiple acute myeloid leukemia (AML) subgroups, venetoclax + FLAG-IDA was effective, elicited deep responses, and had an acceptable safety profile, representing an attractive option as a bridge to allo-SCT for adverse-risk, newly diagnosed, and relapsed/refractory (R/R) AML patients. Read More ›

American Society of Hematology (ASH)

Page 8 of 43